Scilex Holding(us:SCLX)

    0.4197

    -8.12%

    Updated on 2024-12-25

    Open:0.4810
    Close:0.4197
    High:0.4837
    Low:0.3952
    Pre Close:0.4568
    Volume:1.38M
    Amount:582095.50
    Turnover:0.62%
    Shares:220.85M
    MarketCap:92.69M

    About Scilex Holding Company

    Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

    Company Name: Scilex Holding
    Company Address: 960 San Antonio Road
    Employees: 105
    Fiscar Year: 12-31
    IPO Date: 2021-03-04
    CIK: 1820190

    View all SEC Filings

    About

    Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
    Address:960 San Antonio Road

    Market Movers